Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2018-05-11 Director's Dealing
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2018-05-11 English
FORM 4
Director's Dealing
2018-05-09 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer submitted pursuant to the Securities Exchange Act of 1934. The content is a media release about the FDA issuing a complete response letter for a biosimilar drug application. The document does not contain financial statements or detailed financial analysis but is rather an announcement of a regulatory event and company update. The length is about 8,010 characters, which is relatively short and consistent with a press release or regulatory announcement rather than a full financial report. There is no indication of it being an earnings release, annual report, or interim report. It is not a certification or officer attestation. Therefore, the document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2018-05-03 English
Sandoz receives complete response letter from the US FDA for proposed biosimilar rituximab
Regulatory Filings Classification · 95% confidence The document is a press release dated May 2, 2018, announcing that Sandoz (a Novartis division) received a complete response letter (CRL) from the US FDA regarding its biosimilar rituximab application. This is a specific, time-sensitive update regarding regulatory interaction and product development status, rather than a comprehensive financial report (like 10-K or IR) or a general shareholder communication (like DEF 14A or AGM-R). It is a form of regulatory/business update that doesn't fit perfectly into the core financial reporting categories. Since it is a specific announcement about a regulatory outcome, it is best classified as a general Regulatory Filing (RNS) as it is a formal communication disseminated via a news service (Nasdaq Corporate Solutions/Globenewswire) that doesn't align with the more specific categories like Earnings Release (ER) or Legal Proceedings Report (LTR), although it touches upon regulatory matters. Given the options, RNS serves as the best general regulatory announcement fallback.
2018-05-03 English
Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
Earnings Release Classification · 95% confidence The document is a press release dated May 1, 2018, announcing that the FDA has approved Novartis's Kymriah® for a second indication (relapsed or refractory large B-cell lymphoma). It details the clinical trial results (JULIET study), safety information (CRS, toxicities), manufacturing process, and future plans. This content strongly aligns with an Earnings Release (ER) which typically announces key financial or operational milestones, such as major regulatory approvals, often accompanied by brief highlights before the full report. While it contains detailed information, its structure and focus on a single, major event (FDA approval) released via a press announcement format suggest it is the initial announcement of results/developments, rather than a comprehensive quarterly/annual report (10-K or IR) or a management discussion (MDA). Given the context of major product news, ER is the most appropriate fit among the options provided, as it is the initial public announcement of a significant operational/product development milestone. Q2 2018
2018-05-01 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily provides an update on the proposed acquisition of AveXis, including regulatory waiting period expiration and tender offer details. It includes forward-looking statements and references to tender offer filings (Schedule TO and Schedule 14D-9) but does not contain actual financial statements or detailed financial analysis. The document is a regulatory announcement about a merger-related event rather than a full merger filing or a financial report. Given the nature of the content as an SEC Form 6-K providing a corporate event update without substantive financial data, the appropriate classification is Regulatory Filings (RNS). The document length (8476 characters) is sufficient to be more than a brief announcement but does not contain the detailed financial or management discussion typical of other categories. Therefore, the best fit is RNS with high confidence.
2018-05-01 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.